Purpose: We aimed to evaluate the excess direct and indirect costs associated with epilepsy. Methods: From the Danish National Patient Registry (1998-2013), we identified people within all ages with an epilepsy diagnosis and matched them to control individuals. Additionally, partners of people with epilepsy were identified, who were compared with control partners. Direct costs included frequencies and costs of hospitalizations and weighted outpatient use according to diagnosis-related group, and specific outpatient costs based on data from the Danish Ministry of Health. The use and costs of drugs were based on data from the Danish Medicines Agency. The frequencies of visits and hospitalizations, and costs from general practice were derived from data from the National Health Security. Indirect costs included labor supply-based income data, and all social transfer payments obtained from Coherent Social Statistics. Results: A greater percentage of people with epilepsy and their partners compared with respective control subjects received social services (sick pay or disability pension). Those with epilepsy had a lower employment rate than did controls for equivalent periods up to eight years before the diagnosis was made. Mortality was significantly higher in people with epilepsy than in control individuals (hazard ratio 2.38 (95% CI: 2.34, 2.41). The additional direct and indirect annual costs of epilepsy compared with controls were s11,223 for persons with epilepsy and s2,494 for their partners. Conclusion: Epilepsy has major socioeconomic consequences for individual patients, their partners and society.
Introduction
Epilepsy is a common and chronic neurological disorder affecting approximately 1% of people of all ages [1, 2] . Despite diagnostic and therapeutic improvements, refractory epilepsy is relatively frequent and, due to significant comorbidity, is still one of the most common serious brain disorders worldwide. Epilepsy is associated with social stigma, psychosocial adversities, and reduced quality of life for patients and their caregivers and, thus, has a substantial socioeconomic impact [3] [4] [5] [6] .
Studies of the economic impact of epilepsy have mainly focused on questionnaires and other direct or indirect information obtained from selected groups of people with epilepsy, and have documented the combined socioeconomic consequences [7, 8] . Furthermore, those with epilepsy may also find that the disorder has adverse consequences for their partner [3, 6, 9] . We have previously evaluated these combined costs in people with epilepsy by comparing a national sample of persons with epilepsy with controls, documenting significant health and social consequences for adults [2] and long-term consequences for children and their parents [10] [11] [12] compared to controls without epilepsy. However, these estimates only considered the consequences for the individual with epilepsy. A national factual economic estimate of the total disease cost for people with epilepsy and their partners compared with a control group has not previously been attempted.
We therefore aimed to evaluate the total factual costs associated with epilepsy before and after its diagnosis, including health (direct) and social (indirect) costs of the disease, as determined in a national population-based study.
Materials and Methods
In Denmark, it is possible to calculate health sector costs and productivity losses related to diseases because information from public and private hospitals, general practice, privately practicing specialists, medication, social transfers, labor market income and employment for all Danes is registered in central databases. All patient contacts with the hospital system are recorded in the Danish National Patient Registry (NPR) at the time of contact and include the primary diagnosis [13] . The NPR is a time-based national database that includes data from all inpatient and outpatient contacts, meaning that the data that we can extract are representative of everyone in Denmark who has received a diagnosis of epilepsy in public and private hospitals. Since data are available for the entire observation period, we can trace patients retrospectively and prospectively, relative to the time of the epilepsy diagnosis. Furthermore, all contacts in the primary sector (general and specialist practices) and medication use are recorded in the databases of the National Health Security and the Danish Medicine Agency, respectively. There is some underestimation of the number of people with epilepsy, because those with a contact in the general practice sector only, in contrast to the in-and outpatients contacts in hospitals, are not recorded with an epilepsy diagnosis in the NPR.
The economic consequences of epilepsy for patients and their partners were estimated by determining the yearly cost of illness per patient diagnosed with the ICD-10 code for epilepsy (G40.0-9); these codes are given after patient evaluation in each hospital (based on a standardized evaluation of epilepsy). These figures are compared for patients and their spouses with those of an individual matched control group based on gender, age and municipality. The number of cases per control was 1:4. Matches was obtained in >99.9%. The estimated health cost was then divided into annual direct and indirect healthcare costs.
Direct costs, including hospitalization, costs of outpatient visits and uses of medication, were calculated using Diagnosis-Related Group (DRG) weights, and specific outpatient tariffs. These cost estimates were all based on data from the Danish Ministry of Health [2] . The use and costs of drugs were calculated from data from the National Danish Medicine Agency, consisting of the retail price of each drug (including dispensing costs) multiplied by the number of transactions. The frequencies and costs of consultations with general practitioners and other specialists were based on data from National Health Security.
The indirect costs (foregone earnings), which are those related to reduced labor supply, are based on figures from Danish Income Statistics [2] . Social-transfer payments, which are primarily publicly funded in Denmark, were also included. This includes subsistence allowances, pensions, social security, social assistance, publicly funded personal support for education, and others.
Cost-of-illness studies measure the economic burden resulting from disease and illness across a defined population and include direct and indirect costs. As patients leave the national data registers at the time of death, disappearance and emigration, the indirect cost estimate comprises only the production loss related to disease-related work disability. It is important to distinguish health-related costs from monetary transfer payments such as disability and welfare payments. These payments transfer purchasing power to the recipients from general taxpayers, but do not represent net increases in the use of resources, for which reason they are not included in the total cost estimate.
From the NPR, we identified all people who received a first diagnosis of epilepsy between 1997 and 2014. Then, using data from the Civil Registration System and the Statistics Denmark database (which includes information about social factors, marital and cohabiting status, incomes, pensions, etc.) [14] , we randomly selected citizens who had the same age and sex as those with epilepsy. Social compensation was taken into account by selecting control subjects who resided in the same area of the country in which the patients lived, and who had the same civil status. The ratio of control subjects to those with epilepsy was 4:1. Data from people with epilepsy and matched control subjects who could not be identified in the Coherent Social Statistics database (<1%) were excluded from the sample, but more than 99% of the observations in the two groups were successfully matched. Patients and matched control subjects were followed from the year of diagnosis until 2013. Thus, people with an epilepsy diagnosis at the beginning of the period contributed follow-up data over 16 years; those experiencing an epilepsy diagnosis at the end of the period provided pre-diagnosis data, and all those in between provided varying amounts of pre-and post-diagnosis data. If a patient or control was not present in the CPR register on January 1st each year, then the corresponding control or person with epilepsy control was not included in the dataset for that year. People with epilepsy who are absent from the CPR register are typically deceased, in prison, or have emigrated to another country. All partners of people with epilepsy were also identified. A partner is defined as another adult sharing a home (i.e., not a parent-child household) with the subject, irrespective of gender, sexual, familiar, marital or civil status. A similar group of partners for control subjects was identified on the basis of age, gender and sociodemographic status.
Costs were measured on a yearly basis and adjusted to 2009 prices using the general price index. All costs were measured in DKK and converted to Euros using the exchange rate on June 30th 2011 (s1 = 7.45DKK).
The study was approved by the Danish Data Protection Agency. Data were handled in a manner that did not reveal the identity of anyone with epilepsy or of any control subjects, so neither individual nor ethical approval was required. Statistical analysis was done with SAS 9.1.3 (SAS, Inc., Cary, NC). Statistical significance of the cost estimates was assessed by nonparametric bootstrap analyses [15] .
Results
In total, persons aged between 0 and >80 years of age with an epilepsy diagnosis were included and were matched with control subjects. Age distribution is shown in Table 1 . Of these, 52.2% were males. 37.1% were married or co-living -partners of people with epilepsy and controls. Mortality was significantly higher in people with epilepsy than in controls (hazard ratio 2.38 (95% CI: 2.34, 2.41)) ( Fig. 1 ).
Health costs: outpatient clinic, hospital, primary care and drugs
A higher percentage of epilepsy than control subjects were treated in outpatient clinics, were hospitalized, and had contact with the primary care system (Table 2) . Compared with control subjects, a greater proportion of those with epilepsy were taking medication and receiving public support to pay for it (Table 2) . Home care usage was significantly higher among persons with epilepsy (Table 2 ). Persons with epilepsy had greater medical expenses before diagnosis, which increased at the time of diagnosis and rose steadily thereafter (Fig. 2) .
Similar findings were observed in partners, who also had increased use of outpatient services, in-patient admissions, prescription medications, but fewer visits to the physician office visits ( Table 2 ). These greater costs to partners were incurred before and after the time of the epilepsy diagnosis (Fig. 2) .
Indirect costs: social costs, employment rate and income
A greater percentage of people with epilepsy and their partners compared with their respective control subjects received social services, i.e., sick pay or disability pension (Table 2 ). Due to these public services, early retirement and pension age were reduced (as people with epilepsy and their partners were already receiving transfer income) compared with controls. Conversely, a lower proportion of people with epilepsy than control subjects received income from employment (Table 2) . Those with epilepsy and their partners had lower employment rates and higher social transfer rates than control subjects (Table 2) . Patient with epilepsy who were employed had lower income levels as compared to employed controls (Table 3) . People with epilepsy had lower employment rates than did controls over equivalent periods up to eight years before, at the time of, and after the diagnosis of epilepsy (Fig. 2) .
Total health costs per year
The average annual healthcare cost per person per year by cost categories for people with epilepsy in Denmark compared with ageand gender-matched control subjects are presented in Table 3 . The sum of direct net healthcare costs per year (general practitioner services, hospital services and medication) and indirect costs (loss of labor market income) were s for those with epilepsy and s 1791 for their controls, i.e., an additional cost of s. Social transfer payments were all significantly higher in people with epilepsy than in control subjects (Table 3) . People with epilepsy received an annual mean excess social transfer income resulting in net costs including transfers of s. The average excess net costs for the partners were s2494 and the average net costs including transfers were s3335 (Table 3) .
Influence of age and gender on the direct and indirect Costs
Welfare consequences (direct and indirect costs)stratified by age and gender are shown in Fig. 3 . Direct and indirect costs were elevated for all age groups and both genders. The increase in indirect costs associated with epilepsy may be ascribed to increased pension payments, and to lower incomes, particularly among the younger and middle-aged with epilepsy.
Discussion
This study demonstrates that epilepsy has a significant socioeconomic impact on people with the disorder and on their partners before and at the time of diagnosis and thereafter. Compared with age-and gender-matched controls, these two groups had significantly higher rates of morbidity and mortality at all ages, and of contact with all sectors of the healthcare system, including general practice, outpatient clinics and hospital inpatient services. Fig. 2 . Welfare costs in patients and partners before and after diagnosis of epilepsy compared with controls.
The health costs are elevated years prior to diagnose of epilepsy. At time of diagnose, the costs are elevated due to hospitalization and diagnostic procedures. The costs are also elevated after. We do not know when the patients had their first seizure so the period before can be due to underlying disease or misclassification of disease.
People with epilepsy had higher rates of medication use and supported payments for medications. They had lower employment rates and more often received welfare payments. Employed people with epilepsy had lower incomes than employed control subjects and home care usage was almost twice as high in those with epilepsy than in controls.
We have previously reported that epilepsy often has early onset and, because it is commonly a chronic disorder, the influence of the diagnoses on early social prognosis and the impact on direct and especially indirect costs are considerable [8] . Furthermore we have documented the negative long-term impact of epilepsy in childhood and adolescent onset epilepsy [10, 11, 16] . Consistent with the findings of our previous study, here we confirm, with an even larger sample of people with epilepsy, and by the inclusion of home care data as well as the documentation of family costs, that the total expenses and socioeconomic impact are significantly greater for people with epilepsy than they are for controls. This is particularly marked in those whose onset of epilepsy occurs in childhood, adolescence or younger adulthood [10, 11, 16] . Here we aimed to identify the total societal burden of epilepsy, as such we included all ages for analysis. Further analysis would include impact on welfare cost analysis for chronicity, comorbidity and treatment (medication, surgery, vagus stimulation) as these factor may influence the indivial welfare consequences [17] [18] [19] .
Cost of illness methods aim to isolate the economic burden of disease and illness within a defined population, including direct and indirect costs. In this study, the cost of illness was isolated by comparing the patient group with a control group of similar characteristics but without the specific disease. The cost of illness estimate therefore represent all the costs specifically attributable to epilepsy and its comorbidities. Patients and controls were excluded from the data set if they died or otherwise ceased to feature in the dataset. The results of the study therefore reflect the yearly excess cost of a living person with epilepsy relative to a similar person without the disease. Including the mortality-related cost in the estimates would make interpretation of the estimated yearly costs difficult, since high mortality in the epilepsy group would lower the yearly direct cost after diagnosis, not because treatment after diagnosis is effective, but because deceased persons obviously have no requirement for health care. If we had data from the times of diagnosis to the time of death for all patients and controls, we could calculate the direct and productivity costs per person over their lifetime.
As in most other cost of illness analyses, it is difficult to isolate the cost of the disease in question from that of other comorbid conditions. The cost estimates found in this study cannot be definitively attributed to epilepsy, but should be considered as the yearly excess direct health costs and the productivity cost for a living person diagnosed with epilepsy relative to a comparable living person without the illness.
Most people with epilepsy experience it as a chronic neurological disorder, so the disease may have a major influence on their social competence and family relationships, in addition to its considerable negative economic impact [2, 8, 20, 21] . We chose to use a controlled design to estimate the additional cost above that of the background population without an epilepsy diagnosis. If we had compared people with epilepsy with members of the general population, the differences and the socioeconomic impact would have been more pronounced.
Previous studies of the burden of epilepsy have focused on direct costs, e.g., those of hospital services and the use of treatment procedures, such as medication, physiotherapy, etc. [5, 22, 23] . However, epilepsy causes a significant social burden [24] and it is therefore essential also to assess indirect costs. A few studies have evaluated the indirect costs due to the social consequences and found this component not to be insignificant [5, 25] . Epilepsy significantly affects the lives of people with epilepsy, their family members, and caregivers [26] [27] [28] [29] .
This was also found in this study in which the costs for the families À in this case shown for the partners À was significant. We Table 3 Welfare have not included estimates for children; future analyses should include prospective analysis of this factor as well. In addition to the costs to people with epilepsy and their caregivers, additional costs should also include home care, which, in this study, was substantially elevated. There may be various explanations for the higher costs incurred by the partners of people with epilepsy: the disorder may affect family life, through the increased need for care, the lower employment rate and greater need for social care. Another explanation might patients with epilepsy suffers from problems in education, employment [20] but also psychosocial adversities and feeling discriminated may add to the negative social outcome [6] .
Several studies have estimated the annual cost of epilepsy [8, 21, 30] . Taking the average of these studies, the mean annual direct costs have been estimated to be $4748 (adjusted to 2006 values). The mean indirect costs ranged between 12% and 85% of the total annual costs [4] . The estimates in our study were substantially higher than in those studies, and also compared with another European study of the cost of brain diseases [8] . The main Fig. 3 . Welfare consequences by age and gender.
reason for this discrepancy is that the estimates for diagnosis, management, and social costs in particular, are significant. Due to the large number of people with epilepsy, and the early onset of the disorder [10, 11] , the total societal burden is significant. Generally, disorders of the brain cause a substantial societal burden [31] [32] [33] due to the involvement of comorbidities but also social costs [34] . However, it is difficult to obtain a balanced cost estimate between diseases due to differences in mortality rates, comorbidities, age and gender effects and compare effect between heterogeneous disorders.
This study shows that epilepsy has a significant effect on indirect costs, accounting for almost three-quarters of the total costs, of which public transfer and loss of labor market income are the most important components; as such epilepsy has extensive effect on the social prognosis. Epilepsy also has significant consequences for work capabilities, disability pension, social transfer income, and other public support because a substantial proportion of people with epilepsy experience early onset of the disease [10, 11] . Despite the potentially positive effects of treatment like vagus stimulation and epilepsy, the social consequences are significant [18, 19] . Due to chronicity, early onset and high prevalence of epilepsy, the total societal burden of epilepsy is heavy. The impact of epilepsy on work capabilities is considerable and presents prior to the diagnosis of epilepsy. Long-term evaluation of early onset epilepsy shows that the disorder has a major effect on educational and employment rates [10] . This suggests that there is a further need to focus on early identification, the causes of epilepsy, and the effect of disease management on social outcomes. Low employment rates are also seen with other early onset chronic and progressive disorders, e.g., narcolepsy [35] . We believe that several factors may explain this: (1) epilepsy is often a symptom of other brain diseases and patients may have subclinical or clinical symptoms of these other brain conditions long before the epilepsy is diagnosed; (2) people with epilepsy may not be able to seek a pension before they receive a diagnosis, and, thus, they remain employed until their diagnosis is made; (3) people with epilepsy may only seek professional help when they have reached the point at which their social lives are impaired and their symptoms lead to exhaustion; (4) disease management has limited influence on social outcome; and, (5) further disease progression (of the underlying disease or its primary manifestations) accelerates social decline. We have not yet evaluated these factors in detail. This would require a careful evaluation of the subjects' employment and healthcare consumption before they had received their epilepsy diagnosis.
Factors resulting in increased costs associated with epilepsy would be most relevant if disease management (prevention or treatment) affected direct and indirect costs. If this were the case, prevention, effective treatment and early intervention would be very important since daily functioning is already affected by the time that epilepsy is diagnosed. Most treatment modalities mainly focus on eliminating seizures or reduce seizure frequency, and to a lesser degree on their effects on costs and social factors. In contrast, if an intervention is identified that is effective at lowering morbidity, mortality and healthcare use, thereby influencing the socioeconomic costs associated with epilepsy, then it will become even more important to have a means of detecting the early manifestation of brain disorders that lead to epilepsy, and to intervene early. Furthermore, measures that reduce the social consequences are likely to have a significant impact on the burden and negative economic consequences of epilepsy.
We based our current study on reports from all Danish clinics or hospitals registered in the NPR, which represents a complete national patient sample. This was possible because all Danes are registered using social security codes, and for whom linked data including health, medication, social and employment information are collected. As such, these costs cover those of all contacts with the primary and secondary sector (general practice and hospitals), including diagnostic and treatment procedures at the time of diagnosis. Thus, the estimate of the direct costs is a conservative one. All indirect costs, including transfer payment costs, and income levels were included in the analysis. As the aim of the study was to identify the total burden of an epilepsy diagnosis, we included all the cases in the national sample with a first diagnosis of epilepsy, but did not consider the criteria for any other verification of the diagnoses. It would also be valuable to conduct subgroup analyses, for example, of patients with multiple contacts, those with specific comorbidities, and surgical patients, to estimate costs with respect to the severity of the disease. The control group was not defined as a group of healthy subjects; they were selected on the basis of age, gender and geography (the latter to allow adjustment for social factors). Consequently, the study presents the factual determined direct and indirect costs of epilepsy evaluated in a national sample, compared with a random population-based control group of similar age, gender and social composition, over an eight-year period.
In conclusion, the current study found epilepsy to be associated with significantly higher mortality, health-related and social transfer costs, and home care use, and lower levels of employment and income. Epilepsy is also associated with significant impacts on the partners of those with epilepsy. Healthcare professionals should be aware of the possibilities for detecting, diagnosing and managing epilepsy, and ensure that patients receive adequate information about their disorder. Future research should evaluate the effect of early disease identification, disease management, and the effects of epilepsy on socioeconomic factors, work capabilities, and healthcare and social needs, in order to be able to reduce the costs to patients, families and society.
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